Back

The effect of quality of life on all cause mortality in tafamidis treated vs. placebo ATTR-CM patients: post hoc analyses from the ATTR-ACT study

31 August 2026 (12:30 - 12:40)
Organised by: Logo
Congress Presentation Part of: Transforming heart failure with next-generation therapies and mechanisms Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Francesco Cappelli

Careggi University Hospital (AOUC), Florence (Italy)

4 More presentations in this session

Presentation thumbnail
Phase Ib study of intravenous HRS-9057, an arginine vasopressin V2 receptor antagonist, versus oral tolvaptan in congestive heart failure with volume overload despite prior diuretic therapy
Professor W. Ou (CN)
Abstract
Presentation thumbnail
Comparative effectiveness of finerenone versus spironolactone in patients hospitalized with heart failure: a prospective cohort study
Doctor R. Xiao (Chongqing, CN)
Abstract
Presentation thumbnail
Optimizing mineralocorticoid receptor antagonist therapy with sodium zirconium cyclosilicate in heart failure
Doctor C. Basic (Gothenburg, SE)
Abstract
Presentation thumbnail
Pyruvate metabolism enzyme Dlat induces mitochondria protein hyperacetylation to limit fatty acid oxidation in the HFpEF heart
Doctor Y. Wang (CN)
Abstract

Access the full session

Session thumbnail
Transforming heart failure with next-generation therapies and mechanisms

The Event

Event poster

ESC Congress 2026

31 August 2026 12:30 CET
You may be interested in
thumbnail
Congress Presentation
Improved survival with around 5 years of continuous tafamidis treatment among patients with NYHA class III transthyretin amyloid cardiomyopathy
21 May 2022
thumbnail
Congress Presentation
Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes
1 September 2025
thumbnail
Congress Presentation
Health-related quality of life in patients with symptomatic transthyretin amyloid cardiomyopathy treated with acoramidis: an EQ-5D analysis from the ATTRibute-CM study
13 May 2024
thumbnail
Congress Presentation
Temporal changes in quality of life amongst European atrial fibrillation patients: relationship to all-cause mortality. A report from the ESC-EHRA EORP-AF General Long-Term Registry
28 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources